The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients

The second generation tyrosine kinase inhibitor (TKI) dasatinib is a clinically approved drug for chronic myeloid leukemia (CML) as well as Ph(+) acute lymphoblastic leukemia. In addition to its antileukemic effects, dasatinib was shown to impact on normal hematopoiesis and cells of the immune syste...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Schubert, Claudia, Chatain, Nicolas, Braunschweig, Till, Schemionek, Mirle, Feldberg, Kristina, Hoffmann, Melanie, Dufva, Olli, Mustjoki, Satu, Brümmendorf, Tim H., Koschmieder, Steffen
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2017
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471007/
https://ncbi.nlm.nih.gov/pubmed/28423730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16152
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन